Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations. In addition to our broad portfolio, we have an accomplished team of scientists, novel technology platforms and end-to-end capabilities from new target discovery to GMP manufacturing. We believe that combination therapies and a deep understanding of each patientâs cancer will be key drivers of success in substantially expanding the patient population benefiting from current immuno-oncology therapies. At Agenus, we believe we have assembled the capabilities to bring curative treatments to patients. Source
No articles found.
T2 Biosystems, a leader in the development and commercialization of innovative med...
T2 Biosystems, a leader in the development and ...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
Celldex is developing targeted therapeutics to address devastating diseases for wh...
Celldex is developing targeted therapeutics to ...
Wright Medical Group N.V. is a global medical device company focused on Extremitie...
Wright Medical Group N.V. is a global medical d...
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
Join the National Investor Network and get the latest information with your interests in mind.